BackAkero Therapeutics Overview

Akero Therapeutics Selling, General & Admin

Selling, General & Admin expenses for AKRO.

Quarterly SG&A Expenses

$11.35M
↑ 19.87% YoY

As of Sep 30, 2025

Annual SG&A Expenses (TTM)

$43.02M
↑ 14.2% YoY

Trailing 12 months ending Sep 30, 2025

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin